Detailed comparison on parameters like NAV | Returns | Risk | Rating | Analysis
Risk | Very High | Very High |
Rating | 5.0 | 2.0 |
Min SIP Amount | ₹100 | ₹1000 |
Expense Ratio | 1.56 | 1.7 |
NAV | ₹4149.63 | ₹64.32 |
Fund Started | 25 Sep 1995 | 11 Nov 2013 |
Fund Size | ₹34690.03 Cr | ₹10601.94 Cr |
Exit Load | Exit load of 1% if redeemed within 1 months | Exit load of 0.5%, if redeemed within 90 days. |
Risk
Rating
Min SIP Amount
Expense Ratio
NAV
Fund Started
Fund Size
Exit Load
1 Year | 14.23% | 10.06% |
3 Year | 29.16% | 17.51% |
5 Year | 33.56% | 29.49% |
1 Year
3 Year
5 Year
Equity | 98.08% | 96.33% |
Cash | 1.91% | -0.11% |
Equity
Cash
Top 10 Holdings |
|
|
Top 10 Holdings
Name | Assets |
---|---|
BSE Ltd. | 3.47% |
Cholamandalam Financial Holdings Ltd. | 2.87% |
Fortis Healthcare Ltd. | 2.62% |
Persistent Systems Ltd. | 2.52% |
Power Finance Corporation Ltd. | 2.35% |
The Federal Bank Ltd. | 2.27% |
AU Small Finance Bank Ltd. | 2.25% |
Dixon Technologies (India) Ltd. | 2.13% |
Indus Towers Ltd. | 2.12% |
Voltas Ltd. | 2.10% |
Name | Assets |
---|---|
Solar Industries India Ltd. | 3.84% |
Max Healthcare Institute Ltd. | 3.65% |
Dixon Technologies (India) Ltd. | 3.59% |
JK Cement Ltd. | 2.64% |
Persistent Systems Ltd. | 2.61% |
Max Financial Services Ltd. | 2.37% |
HDFC Asset Management Company Ltd. | 2.20% |
The Indian Hotels Company Ltd. | 2.20% |
Mankind Pharma Ltd. | 2.15% |
Abbott India Ltd. | 2.10% |
Name | Akshay Sharma | Vivek Sharma |
Start Date | 01 Dec 2022 | 15 Feb 2025 |
Name
Start Date
Description | The scheme aims at long term growth of capital through research based investment approach. The funds will be invested in Equity and equity related instruments ,and there will be an exposure to debt and money market instruments also. | The scheme seeks to achieve long-term capital appreciation by predominantly investing in equity & equity related instruments of mid cap companies. |
Launch Date | 25 Sep 1995 | 11 Nov 2013 |
Description
Launch Date